UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050148
Receipt number R000056820
Scientific Title Observational Study on the long term prognosis in A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis
Date of disclosure of the study information 2023/01/27
Last modified on 2024/01/29 13:37:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational Study on the long term prognosis in A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis

Acronym

Observational Study in NEXUS Study

Scientific Title

Observational Study on the long term prognosis in A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis

Scientific Title:Acronym

Observational Study in NEXUS Study

Region

Japan


Condition

Condition

Patients with surgically resectable BRAF V600E mutant colorectal metastasis.

Classification by specialty

Gastroenterology Gastrointestinal surgery Hepato-biliary-pancreatic surgery
Chest surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The purpose is to analyze the long-term prognosis after the end of the observation period of the NEXUS study.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Overall survival

Key secondary outcomes

Progression free survival
Disease-free survival
Incidence of adverse events


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with resectable metastatic colorectal cancer with BRAF V600E mutation who were enrolled in the NEXUS study and consented to the secondary use of information obtained in the NEXUS study and consented to participate in the NEXUS study-observational study.

Key exclusion criteria

Patients whose consent has not been withdrawn will be included.

Target sample size

44


Research contact person

Name of lead principal investigator

1st name Takayuki
Middle name
Last name Yoshino

Organization

National Cancer Center Hospital East

Division name

Department of Gastrointestinal Oncology

Zip code

277-8577

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

TEL

0471331111

Email

nexus_core@east.ncc.go.jp


Public contact

Name of contact person

1st name Shin
Middle name
Last name kobayashi

Organization

National Cancer Center Hospital East

Division name

Department of Hepatobiliary and Pancreatic Surgery

Zip code

277-8577

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

TEL

0471331111

Homepage URL


Email

ymikamot@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cancer Center Research Ethics Review Committee

Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

Tel

04-7133-1111

Email

NCC_IRBoffice@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 07 Month 04 Day

Date of IRB

2022 Year 07 Month 04 Day

Anticipated trial start date

2022 Year 09 Month 13 Day

Last follow-up date

2029 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The design of this study is a multicenter prospective cohort study, using only the secondary use of existing information obtained in routine practice after the observation period of the NEXUS study and the registry data of the NEXUS study-TR study. The observation period is from the day following the end of the observation period of the NEXUS study to the same day 5 years after the last case registration date of the NEXUS study, and the existing information on long-term prognosis and safety of NEXUS study enrollment cases during the above period is collected.


Management information

Registered date

2023 Year 01 Month 26 Day

Last modified on

2024 Year 01 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056820


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name